Aurora Cannabis

Aurora’s moat relies on regulatory and operational intangibles rather than consumer brand power. The company operates EU‑GMP certified facilities and uniquely manufactures domestically in Germany at Leuna, which, together with Canadian GMP capacity, supports compliant, reliable supply across regulated markets.

This provides barriers to entry in markets that require GMP certification and controlled import channels. Still, these are not impenetrable: EU‑GMP certification is attainable by well‑capitalized rivals, and Germany’s liberalization plus growing imports imply intensifying competition over time.

Switching costs for prescribers and patients are modest, with partial stickiness from insurance formularies and consistent quality, but not enough to be durable on their own. We see limited cost advantage beyond scale procurement and manufacturing learning effects.

Efficient scale exists in select export markets with quota or license constraints, but those protections may erode as more suppliers qualify. Overall, we credit modest, execution‑dependent advantages rather than a thick, enduring moat.